


## CLAIMS

What is claimed is:

- 5 1. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of formula (I):



wherein:

- 10  $R^2$  is H, F, Cl, Br, I, cyano, nitro,  $COR^a$ ,  $COOR^a$ ,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio,  $C_{1-6}$  haloalkyl,  $C_{3-7}$  cycloalkyl, phenyl,  $C_{2-9}$  heterocyclyl, (phenyl)- $C_{1-6}$  alkylene, ( $C_{2-9}$  heterocyclyl)- $C_{1-6}$  alkylene, or ( $C_{3-7}$  cycloalkyl)- $C_{1-6}$  alkylene; wherein  $R^a$  is H,  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl, or ( $C_{3-7}$  cycloalkyl)- $C_{1-6}$  alkylene;
- 15  $R^3$  is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio,  $C_{1-6}$  haloalkyl,  $C_{3-7}$  cycloalkyl, phenyl,  $C_{2-9}$  heterocyclyl, (phenyl)- $C_{1-6}$  alkylene, ( $C_{2-9}$  heterocyclyl)- $C_{1-6}$  alkylene, or ( $C_{3-7}$  cycloalkyl)- $C_{1-6}$  alkylene
- or  $R^2$  and  $R^3$  taken together with the phenyl ring to which they are attached
- 20 form a naphthyl;
- $R^4$  is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino,  $COR^b$ ,  $COOR^b$ ,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio,  $C_{1-6}$  haloalkyl,  $C_{3-7}$  cycloalkyl, phenyl,  $C_{2-9}$  heterocyclyl, (phenyl)- $C_{1-6}$  alkylene, ( $C_{2-9}$  heterocyclyl)- $C_{1-6}$  alkylene, or

- (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene; wherein R<sup>b</sup> is H, C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, or (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene;
- R<sup>5</sup> is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, or C<sub>3-7</sub> cycloalkyl;
- 5 R<sup>6</sup> is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, C<sub>3-7</sub> cycloalkyl, phenyl, C<sub>2-9</sub> heterocyclyl, (phenyl)-C<sub>1-6</sub> alkylene, (C<sub>2-9</sub> heterocyclyl)-C<sub>1-6</sub> alkylene, or (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene;
- X is NH, O, or CH<sub>2</sub>;
- 10 W is S, O, or =N-CN;
- each of R<sup>7</sup> and R<sup>8</sup> is independently selected from H, C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene, phenyl, and (phenyl)-C<sub>1-6</sub> alkylene, provided at least one of R<sup>7</sup> and R<sup>8</sup> is not H;
- wherein each of the above hydrocarbyl or heterocarbyl moieties can be
- 15 optionally substituted with between 1 and 3 substituents selected from F, Cl, Br, I, cyano, hydroxy, nitro, amino, COR<sup>c</sup>, COOR<sup>c</sup>, C<sub>1-3</sub> alkyl, C<sub>1-3</sub> alkoxy, C<sub>1-3</sub> alkylthio, C<sub>1-3</sub> haloalkyl, and C<sub>3-6</sub> cycloalkyl; wherein R<sup>c</sup> is H or C<sub>1-6</sub> alkyl;
- provided when W is O, X is NH, and R<sup>7</sup> and R<sup>8</sup> are each methyl, and R<sup>3</sup>, R<sup>4</sup>,
- 20 R<sup>5</sup>, and R<sup>6</sup> are each H, then R<sup>2</sup> is not H, 2-chlorophenyl, or 3-quinolinyl; and pharmaceutically acceptable salts, esters, amides, and hydrates thereof.
2. A composition of claim 1, wherein W is O.
- 25 3. A composition of claim 1, wherein R<sup>2</sup> and R<sup>4</sup> are not hydrogen.
4. A composition of claim 1, wherein X is CH<sub>2</sub>.
5. A composition of claim 1, wherein X is NH.
- 30 6. A composition of claim 1, wherein each of R<sup>7</sup> and R<sup>8</sup> is independently selected from methyl, ethyl, and propyl.

7. A composition of claim 1, wherein at least two of  $R^3$ ,  $R^5$ , and  $R^6$  are H.
8. A composition of claim 1, wherein  $R^2$  is H, Cl, Br, I, methyl, halomethyl, cyano, amino, C<sub>2-9</sub> heterocyclyl, phenyl, or phenyl substituted with hydroxy, thiol, nitro, cyano, or halo.
9. A composition of claim 8, wherein  $R^2$  is Cl, Br, I, methyl, cyano, C<sub>2-9</sub> heteroaryl, phenyl, or phenyl substituted with hydroxy, thiol, or halo.
10. A composition of claim 1, wherein  $R^3$  is H or methyl.
11. A composition of claim 10, wherein  $R^3$  is H.
12. A composition of claim 1, wherein  $R^4$  is H, Cl, Br, I, methyl, halomethyl, cyano, amino, C<sub>2-9</sub> heterocyclyl, phenyl, or phenyl substituted with hydroxy, thiol, nitro, cyano, or halo.
13. A composition of claim 12, wherein  $R^4$  is H, Cl, Br, I, or methyl.
14. A composition of claim 1, wherein  $R^5$  is H, Cl, Br, I, methyl, halomethyl, methoxy, thiomethyl, ethyl, ethoxy, or thioethyl.
15. A composition of claim 14, wherein  $R^5$  is H, methyl, or Cl.
16. A composition of claim 1, wherein the stereochemistry of the two dioxane chiral centers is (S,S).
17. A composition of claim 1, wherein said compound of formula (I) is selected from: 1-(2-Bromo-phenyl)-3-(2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; 1-Biphenyl-2-yl-3-(2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and 1-(2,3-Dichloro-phenyl)-3-(2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.

18. A composition of claim 1, wherein said compound of formula (I) is selected from: 1-(4-Bromo-2-chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2,4-Dibromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2,4-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2-Chloro-5-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-thiophen-2-yl-phenyl)-urea;  
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-iodo-phenyl)-urea;  
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(4-iodo-phenyl)-urea;  
1-(4-Bromo-2-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2-Bromo-4-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2-Cyano-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(3'-Chloro-biphenyl-2-yl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2,5-Dimethyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and  
1-Biphenyl-2-yl-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.
19. A composition of claim 1, wherein said compound of formula (I) is selected from: 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-trifluoromethyl-phenyl)-urea;  
1-(4-Bromo-3-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;

- 1-(2-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
- 1-(2,5-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)- urea;
- 5 1-(2-Chloro-5-trifluoromethyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
- 1-(2-Bromo-phenyl)-3-((4R,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and
- 10 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-thiophen-3-yl-phenyl)-urea.
20. A composition of claim 1, wherein said compound of formula (I) is selected from: 1-(2,4-Dimethyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
- 15 1-(2-Chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
- 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-fluoro-phenyl)-urea;
- 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-o-tolyl-urea;
- 20 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-nitro-phenyl)-urea;
- 2-(2-Bromo-phenyl)-N-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-acetamide;
- ((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-carbamic acid 2-chloro-phenyl ester;
- 25 1-(4-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
- 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-methoxy-phenyl)-urea;
- 30 1-(4-Chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
- 2-[3-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-ureido]-benzoic acid;

2-[3-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-ureido]-benzoic acid methyl ester;

1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-isopropyl-phenyl)-urea;

5 1-(2,6-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;


1-(3-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;

10 1-(2,4-Difluoro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and

1-(3-Chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.

21. A compound of formula (Ia):

15



(Ia)

wherein:

R<sup>2</sup> is H, F, Cl, Br, I, cyano, nitro, COR<sup>a</sup>, COOR<sup>a</sup>, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, C<sub>3-7</sub> cycloalkyl, phenyl, C<sub>2-9</sub> heterocyclyl, (phenyl)-C<sub>1-6</sub> alkylene, (C<sub>2-9</sub> heterocyclyl)-C<sub>1-6</sub> alkylene, or (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene; wherein R<sup>a</sup> is H, C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, or (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene;

20

R<sup>3</sup> is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, C<sub>3-7</sub> cycloalkyl, phenyl, C<sub>2-9</sub> heterocyclyl,

(phenyl)-C<sub>1-6</sub> alkylene, (C<sub>2-9</sub> heterocyclyl)-C<sub>1-6</sub> alkylene, or (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene

or R<sup>2</sup> and R<sup>3</sup> taken together with the phenyl ring to which they are attached form a naphthyl;

5 R<sup>4</sup> is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, COR<sup>b</sup>, COOR<sup>b</sup>, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, C<sub>3-7</sub> cycloalkyl, phenyl, C<sub>2-9</sub> heterocyclyl, (phenyl)-C<sub>1-6</sub> alkylene, (C<sub>2-9</sub> heterocyclyl)-C<sub>1-6</sub> alkylene, or (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene; wherein R<sup>b</sup> is H, C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, or (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene;

10 R<sup>5</sup> is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, or C<sub>3-7</sub> cycloalkyl;

R<sup>6</sup> is H, F, Cl, Br, I, cyano, hydroxy, nitro, amino, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, C<sub>3-7</sub> cycloalkyl, phenyl, C<sub>2-9</sub> heterocyclyl, (phenyl)-C<sub>1-6</sub> alkylene, (C<sub>2-9</sub> heterocyclyl)-C<sub>1-6</sub> alkylene, or (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene;

15

X is NH, O, or CH<sub>2</sub>;

W is S, O, or =N-CN;

each of R<sup>7</sup> and R<sup>8</sup> is independently selected from H, C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, (C<sub>3-7</sub> cycloalkyl)-C<sub>1-6</sub> alkylene, phenyl, and (phenyl)-C<sub>1-6</sub> alkylene,

20 provided at least one of R<sup>7</sup> and R<sup>8</sup> is not H;

wherein each of the above hydrocarbonyl or heterocarbonyl moieties can be

optionally substituted with between 1 and 3 substituents selected from

F, Cl, Br, I, cyano, hydroxy, nitro, amino, COR<sup>c</sup>, COOR<sup>c</sup>, C<sub>1-3</sub> alkyl, C<sub>1-3</sub> alkoxy, C<sub>1-3</sub> alkylthio, C<sub>1-3</sub> haloalkyl, and C<sub>3-6</sub> cycloalkyl; wherein R<sup>c</sup> is

25 H or C<sub>1-6</sub> alkyl;

provided when W is O, X is NH, and R<sup>7</sup> and R<sup>8</sup> are each methyl, and R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are each H, then R<sup>2</sup> is not H, Br, phenyl, 2-chlorophenyl, or 3-quinoliny;

provided when W is O, X is NH, and R<sup>7</sup> and R<sup>8</sup> are each methyl, and R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are each H, then R<sup>3</sup> is not Cl nor is R<sup>3</sup> taken together with R<sup>2</sup>;

30

and

provided when W is O, X is NH, and R<sup>7</sup> and R<sup>8</sup> are each methyl, and R<sup>2</sup>, R<sup>5</sup>, and R<sup>6</sup> are each H, then R<sup>4</sup> is not Cl;

and pharmaceutically acceptable salts, esters, amides, and hydrates thereof.

22. A compound of claim 21, wherein W is O.
- 5 23. A compound of claim 21, wherein R<sup>2</sup> and R<sup>4</sup> are not hydrogen.
24. A compound of claim 21, wherein X is CH<sub>2</sub>.
25. A compound of claim 21, wherein X is NH.
- 10 26. A compound of claim 21, wherein each of R<sup>7</sup> and R<sup>8</sup> is independently selected from methyl, ethyl, and propyl.
27. A compound of claim 21, wherein at least two of R<sup>3</sup>, R<sup>5</sup>, and R<sup>6</sup> are H.
- 15 28. A compound of claim 21, wherein R<sup>2</sup> is H, Cl, Br, I, methyl, halomethyl, cyano, amino, C<sub>2-9</sub> heterocyclyl, phenyl, or phenyl substituted with hydroxy, thiol, nitro, cyano, or halo.
- 20 29. A compound of claim 28, wherein R<sup>2</sup> is Cl, Br, I, methyl, cyano, C<sub>2-9</sub> heteroaryl, phenyl, or phenyl substituted with hydroxy, thiol, or halo.
30. A compound of claim 21, wherein R<sup>3</sup> is H or methyl.
- 25 31. A compound of claim 30, wherein R<sup>3</sup> is H.
32. A compound of claim 21, wherein R<sup>4</sup> is H, Cl, Br, I, methyl, halomethyl, cyano, amino, C<sub>2-9</sub> heterocyclyl, phenyl, or phenyl substituted with hydroxy, thiol, nitro, cyano, or halo.
- 30 33. A compound of claim 32, wherein R<sup>4</sup> is H, Cl, Br, I, or methyl.



34. A compound of claim 21, wherein R<sup>5</sup> is H, Cl, Br, I, methyl, halomethyl, methoxy, thiomethyl, ethyl, ethoxy, or thioethyl.
35. A compound of claim 34, wherein R<sup>5</sup> is H, methyl, or Cl.
36. A compound of claim 21, wherein the stereochemistry of the two chiral centers is (S,S).
37. A compound of claim 21, wherein said compound of formula (Ia) is selected from: 1-(4-Bromo-2-chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2,4-Dibromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2,4-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2-Chloro-5-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-thiophen-2-yl-phenyl)-urea;  
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-iodo-phenyl)-urea;  
1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(4-iodo-phenyl)-urea;  
1-(4-Bromo-2-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2-Bromo-4-methyl-phenyl)-3-((4S, 5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(2-Cyano-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;  
1-(3'-Chloro-biphenyl-2-yl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and  
1-(2,5-Dimethyl-phenyl)-3-((4S, 5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.

38. A compound of claim 21, wherein said compound of formula (Ia) is selected from: 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-trifluoromethyl-phenyl)-urea;
- 5 1-(4-Bromo-3-methyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)- urea;
- 1-(2,5-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)- urea;
- 10 1-(2-Chloro-5-trifluoromethyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and
- 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-thiophen-3-yl-phenyl)-urea.
39. A compound of claim 21, wherein said compound of formula (Ia) is selected from: 1-(2,4-Dimethyl-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
- 15 1-(2-Chloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
- 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-fluoro-phenyl)-urea;
- 20 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-o-tolyl-urea;
- 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-nitro-phenyl)-urea;
- 25 2-(2-Bromo-phenyl)-N-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-acetamide;
- ((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-carbamic acid 2-chloro-phenyl ester;
- 1-(4-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;
- 30 1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-methoxy-phenyl)-urea;
- 2-[3-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-ureido]-benzoic acid;

2-[3-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-ureido]-benzoic acid methyl ester;

1-((4S,5S)-2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(2-isopropyl-phenyl)-urea;

5 1-(2,6-Dichloro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea;

1-(3-Bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea; and

10 1-(2,4-Difluoro-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea.

40. A method for treating obesity, said method comprising administering to a subject a pharmaceutically-effective amount of a pharmaceutical composition of claim 1.

15

41. A method for treating a sleep/wake disorder, said method comprising administering to a subject a pharmaceutically-effective amount of a pharmaceutical composition of claim 1.

20

42. A method of claim 41, wherein said sleep/wake disorder is selected from insomnia, narcolepsy, jet lag, and sleep apnea.

43. A method for treating a disease or condition mediated by an orexin-2 receptor, said method comprising administering to a subject a pharmaceutically-effective amount of a pharmaceutical composition of claim 1.

25

44. A method for inhibiting an orexin-2 receptor, said method comprising contacting said receptor with a compound of claim 1.

30

45. A method of claim 44, wherein said orexin-2 receptor is human.

- 46. A method of claim 44, wherein said compound is selective for orexin-2 receptor over orexin-1 receptor by a factor of at least 10.
- 47. A method of claim 46, wherein said factor is at least 100.

5